These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

515 related items for PubMed ID: 8466073

  • 21. Characterization of the aggregation responses of camel platelets.
    Al Ghumlas AK, Gader AG.
    Vet Clin Pathol; 2013 Sep; 42(3):307-13. PubMed ID: 23919654
    [Abstract] [Full Text] [Related]

  • 22. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis.
    Folts J.
    Circulation; 1991 Jun; 83(6 Suppl):IV3-14. PubMed ID: 2040070
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Antithrombotic effects of the thromboxane A2 antagonist, SQ 28,668, in vitro and in the coronary circulation in vivo.
    Ogletree ML, Harris DN, Heran CL, Phillips MB, Michel IM, Goldenberg HJ.
    Eicosanoids; 1988 Jun; 1(2):85-91. PubMed ID: 2856188
    [Abstract] [Full Text] [Related]

  • 26. rLj-RGD3, a novel recombinant toxin protein from Lampetra japonica, prevents coronary thrombosis-induced acute myocardial infarction by inhibiting platelet functions in rats.
    Wang S, Jiang J, Wang Y, Jia Q, Dai S, Wang Y, Lv L, Wang J.
    Biochem Biophys Res Commun; 2018 Mar 25; 498(1):240-245. PubMed ID: 29407168
    [Abstract] [Full Text] [Related]

  • 27. Correlation between the in vivo efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) and ex vivo platelet inhibition.
    Huang J, Rebello SS, Faul JD, Lucchesi BR.
    Pharmacology; 1999 May 25; 58(5):252-64. PubMed ID: 10087466
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Arachidonate metabolism, 5-hydroxytryptamine release and aggregation in human platelets activated by palmitaldehyde acetal phosphatidic acid.
    Brammer JP, Maguire MH.
    Br J Pharmacol; 1984 May 25; 82(1):61-72. PubMed ID: 6428500
    [Abstract] [Full Text] [Related]

  • 30. Inhibition by nitroglycerin of canine platelet aggregation and cyclic flow reductions in stenosed coronary arteries.
    Tanaka T, Morishima Y, Watanabe K, Takahashi M, Shibano T.
    Methods Find Exp Clin Pharmacol; 1995 Dec 25; 17(10):693-700. PubMed ID: 9053590
    [Abstract] [Full Text] [Related]

  • 31. Acquisition and aggregation of canine blood platelets: basic mechanisms of function and differences because of breed origin.
    Clemmons RM, Meyers KM.
    Am J Vet Res; 1984 Jan 25; 45(1):137-44. PubMed ID: 6422804
    [Abstract] [Full Text] [Related]

  • 32. Characterization and platelet inhibitory activity of bitistatin, a potent arginine-glycine-aspartic acid-containing peptide from the venom of the viper Bitis arietans.
    Shebuski RJ, Ramjit DR, Bencen GH, Polokoff MA.
    J Biol Chem; 1989 Dec 25; 264(36):21550-6. PubMed ID: 2600082
    [Abstract] [Full Text] [Related]

  • 33. Platelet activation and subsequent inhibition by plasmin and recombinant tissue-type plasminogen activator.
    Penny WF, Ware JA.
    Blood; 1992 Jan 01; 79(1):91-8. PubMed ID: 1530814
    [Abstract] [Full Text] [Related]

  • 34. Epinephrine induces Ca2+ uptake in human blood platelets.
    Owen NE, Feinberg H, Le Breton GC.
    Am J Physiol; 1980 Oct 01; 239(4):H483-H488. PubMed ID: 7425140
    [Abstract] [Full Text] [Related]

  • 35. Investigations on 5-HT₄ receptor expression and effects of tegaserod on human platelet aggregation in vitro.
    Serebruany VL, El Mouelhi M, Pfannkuche HJ, Rose K, Marro M, Angiolillo DJ.
    Am J Ther; 2010 Oct 01; 17(6):543-52. PubMed ID: 19797939
    [Abstract] [Full Text] [Related]

  • 36. Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis.
    Przyklenk K, Frelinger AL, Linden MD, Whittaker P, Li Y, Barnard MR, Adams J, Morgan M, Al-Shamma H, Michelson AD.
    J Thromb Haemost; 2010 Feb 01; 8(2):331-40. PubMed ID: 19922435
    [Abstract] [Full Text] [Related]

  • 37. The effects of alpha 2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries.
    Bush LR, Campbell WB, Kern K, Tilton GD, Apprill P, Ashton J, Schmitz J, Buja LM, Willerson JT.
    Circ Res; 1984 Nov 01; 55(5):642-52. PubMed ID: 6488486
    [Abstract] [Full Text] [Related]

  • 38. Prevention of experimental carotid artery thrombosis by applaggin.
    Rote WE, Mu DX, Roncinske RA, Frelinger AL, Lucchesi BR.
    J Pharmacol Exp Ther; 1993 Nov 01; 267(2):809-14. PubMed ID: 8246155
    [Abstract] [Full Text] [Related]

  • 39. Platelet-mediated thrombosis in stenosed canine coronary arteries: inhibition by nicergoline, a platelet-active alpha-adrenergic antagonist.
    Bolli R, Ware JA, Brandon TA, Weilbaecher DG, Mace ML.
    J Am Coll Cardiol; 1984 Jun 01; 3(6):1417-26. PubMed ID: 6715702
    [Abstract] [Full Text] [Related]

  • 40. Short-term and long-term role of platelet activating factor as a mediator of in vivo platelet aggregation.
    Golino P, Ambrosio G, Ragni M, Pascucci I, Triggiani M, Oriente A, McNatt J, Buja LM, Condorelli M, Chiariello M.
    Circulation; 1993 Sep 01; 88(3):1205-14. PubMed ID: 8353882
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.